FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387433145> ?p ?o ?g. }

• W4387433145 abstract "Abstract Disclosure: S.G. Goud: None. A. Siddiqui: None. M. Alkhathlan: None. C.Y. Fan: None. Introduction: Immune checkpoint inhibitors such as pembrolizumab (Keytruda) used in the treatment of various cancers are associated with immune mediated endocrinopathies, among which thyroid dysfunction and pituitary hypophysitis are common, whereas hypoparathyroidism is rare. We report a case of primary hypoparathyroidism and hypocalcemia with pembrolizumab. Clinical Case: 58-year-old male with metastatic urothelial cell carcinoma, status post neoadjuvant chemotherapy with gemcitabine and cisplatin in 2017, followed by radical cystectomy with recurrence of metastasis in 2018, who was started on Keytruda every three weeks. After 10 months, he developed immune mediated hypothyroidism treated with levothyroxine. After 33 months on Keytruda, he developed hematochezia with constipation and intermittent abdominal pain. Colonoscopy showed findings consistent with autoimmune colitis; Keytruda was held and colitis was treated with tapering steroids. Surveillance imaging showed stable disease, so Keytruda continued to be held. After 7 months of holding Keytruda, on routine blood work he had a critically low calcium level of 5.5 mg/dl (8.4-10.2 mg/dl) with tingling and numbness in his hands, muscle spasms, generalized weakness, and fatigue for the past few weeks. On exam there was no Trousseau’s sign, Chvostek's sign, or gait ataxia. Hemodynamically stable. Labs showed lowest corrected calcium of 5.5, normal renal function, low vitamin D of 8 ng/ml (30-100 ng/ml), elevated phosphorus of 6.3 mg/dl (2.5-4.5 mg/dl), and normal magnesium. PTH was frankly low at 12.7 pg/ml (15-65 pg/ml), indicating primary hypoparathyroidism. ACTH stimulation test was normal. Retrospective review of the labs from oncology office records showed gradual, progressive hypocalcemia for a few months prior to presentation, with calcium levels ranging between 6.7 to 7.7 mg/dl. Of note, calcium prior to pembrolizumab was normal at 9.4 mg/dl. He was treated with IV calcium gluconate and then transitioned to calcium carbonate (CaCO3) 500 mg TID, calcitriol 0.5 mg BID, and Vit D 50,000 IU twice weekly. Hydrochlorothiazide (HCTZ) added as calcium remained low. After three days calcium improved to 7 mg/dl range and he was discharged. Calcium levels checked periodically after discharge ranged from 8 to 9 mg/dl (8.4-10.2 mg/dl), and phosphorus levels normalized. CaCO3 dose was adjusted accordingly, Vit D was changed to 50,000 IU weekly based on a level of 71 ng/dl after 3 months, and HCTZ was discontinued after 6 months. PTH was still low at 9.7 pg/ml (15-65 pg/ml) 6 months after discharge, off pembrolizumab for over a year. Calcium sensing receptor (CaSR) activating antibody was not checked in our case. Conclusion: It is important clinicians be aware of the risk for hypocalcemia and its unpredictable presentation to help with timely recognition and management. Presentation: Saturday, June 17, 2023" @default.
• W4387433145 created "2023-10-09" @default.
• W4387433145 creator A5030758588 @default.
• W4387433145 creator A5040240893 @default.
• W4387433145 creator A5068529014 @default.
• W4387433145 creator A5079458051 @default.
• W4387433145 date "2023-10-01" @default.
• W4387433145 modified "2023-10-09" @default.
• W4387433145 title "SAT220 Rare Case Of Pembrolizumab Induced Primary Hypoparathyroidism" @default.
• W4387433145 doi "https://doi.org/10.1210/jendso/bvad114.517" @default.
• W4387433145 hasPublicationYear "2023" @default.
• W4387433145 type Work @default.
• W4387433145 citedByCount "0" @default.
• W4387433145 crossrefType "journal-article" @default.
• W4387433145 hasAuthorship W4387433145A5030758588 @default.
• W4387433145 hasAuthorship W4387433145A5040240893 @default.
• W4387433145 hasAuthorship W4387433145A5068529014 @default.
• W4387433145 hasAuthorship W4387433145A5079458051 @default.
• W4387433145 hasBestOaLocation W43874331451 @default.
• W4387433145 hasConcept C121608353 @default.
• W4387433145 hasConcept C126322002 @default.
• W4387433145 hasConcept C141071460 @default.
• W4387433145 hasConcept C2775883008 @default.
• W4387433145 hasConcept C2777701055 @default.
• W4387433145 hasConcept C2778435480 @default.
• W4387433145 hasConcept C2779053571 @default.
• W4387433145 hasConcept C2780057760 @default.
• W4387433145 hasConcept C2781054515 @default.
• W4387433145 hasConcept C526584372 @default.
• W4387433145 hasConcept C526805850 @default.
• W4387433145 hasConcept C71924100 @default.
• W4387433145 hasConcept C90924648 @default.
• W4387433145 hasConceptScore W4387433145C121608353 @default.
• W4387433145 hasConceptScore W4387433145C126322002 @default.
• W4387433145 hasConceptScore W4387433145C141071460 @default.
• W4387433145 hasConceptScore W4387433145C2775883008 @default.
• W4387433145 hasConceptScore W4387433145C2777701055 @default.
• W4387433145 hasConceptScore W4387433145C2778435480 @default.
• W4387433145 hasConceptScore W4387433145C2779053571 @default.
• W4387433145 hasConceptScore W4387433145C2780057760 @default.
• W4387433145 hasConceptScore W4387433145C2781054515 @default.
• W4387433145 hasConceptScore W4387433145C526584372 @default.
• W4387433145 hasConceptScore W4387433145C526805850 @default.
• W4387433145 hasConceptScore W4387433145C71924100 @default.
• W4387433145 hasConceptScore W4387433145C90924648 @default.
• W4387433145 hasIssue "Supplement_1" @default.
• W4387433145 hasLocation W43874331451 @default.
• W4387433145 hasOpenAccess W4387433145 @default.
• W4387433145 hasPrimaryLocation W43874331451 @default.
• W4387433145 hasRelatedWork W1599757615 @default.
• W4387433145 hasRelatedWork W1980168196 @default.
• W4387433145 hasRelatedWork W2258962363 @default.
• W4387433145 hasRelatedWork W2386249179 @default.
• W4387433145 hasRelatedWork W2977292099 @default.
• W4387433145 hasRelatedWork W2977765530 @default.
• W4387433145 hasRelatedWork W3031948020 @default.
• W4387433145 hasRelatedWork W3032806774 @default.
• W4387433145 hasRelatedWork W3140566510 @default.
• W4387433145 hasRelatedWork W4221005098 @default.
• W4387433145 hasVolume "7" @default.
• W4387433145 isParatext "false" @default.
• W4387433145 isRetracted "false" @default.
• W4387433145 workType "article" @default.